1. Metabolic Enzyme/Protease
  2. Stearoyl-CoA Desaturase (SCD)

PluriSln 1 (Synonyms: NSC 14613)

Cat. No.: HY-15700 Purity: 99.53%
Handling Instructions

PluriSln 1 is an inhibitor of stearoyl-coA desaturase (SCD), and is a pluripotent cell-specific inhibitor.

For research use only. We do not sell to patients.
PluriSln 1 Chemical Structure

PluriSln 1 Chemical Structure

CAS No. : 91396-88-2

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 79 In-stock
10 mg USD 72 In-stock
50 mg USD 226 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Featured Recommendations

Related Small Molecules:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

PluriSln 1 is an inhibitor of stearoyl-coA desaturase (SCD), and is a pluripotent cell-specific inhibitor.

IC50 & Target

SCD[1]

In Vitro

PluriSln 1, a small-molecule inhibitor of stearoyl-coA desaturase (SCD), on induced pluripotent stem cells (iPS)-derived cardiomyocytes (CM). PluriSln 1 treatment significantly decreases the mRNA and protein level of Nanog, a marker for both cell pluripotency and tumor progression; importantly, we provide evidence that PluriSln 1 treatment at 20 µM for 1 day significantly induces the apoptosis of Nanog-positive iPS derivates (iPSD). In addition, PluriSln 1 treatment at 20 µM for 4 days diminished Nanog-positive stem cells in cultured iPSD while not increasing apoptosis of iPS-derived CM. To investigate whether PluriSln 1 treatment prevents tumorigenicity of iPSD after cell transplantation, we intramyocardially injected PluriSln 1- or DMSO-treated iPSD in a mouse model of myocardial infarction (MI). DMSO-treated iPSD readily formed Nanog-expressing tumors 2 weeks after injection, which is prevented by treatment with PluriSln 1. Moreover, treatment with PluriSln 1 does not change the expression of cTnI, α-MHC, or MLC-2v, markers of cardiac differentiation (P>0.05, n=4). Importantly, PluriSln 1-treated iPS-derived CM exhibits the ability to engraft and survive in the infarcted myocardium[1].

References
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 4.6896 mL 23.4478 mL 46.8955 mL
5 mM 0.9379 mL 4.6896 mL 9.3791 mL
10 mM 0.4690 mL 2.3448 mL 4.6896 mL
Please refer to the solubility information to select the appropriate solvent.
Cell Assay
[1]

PluriSln 1 is prepared in DMSO (10 mM) and stored, and then diluted with appropriate medium before use[1].

The differentiation of iPS cells to cardiomyocytes (CM) is induced by embryoid body (EB) formation. When iPS cells reached 70% confluency in 10-cm dishes, cells are digested using 0.25% trypsin/EDTA. Cell pellets are re-suspended in differentiation medium (DMEM with 20% FBS and 10 ng/mL BMP4) to a final concentration of 200,000 cells/mL. Cell suspensions are added to 6-well plates with Ulta-Low Attachment surfaces for 4 d to initiate EB formation. On day 5, EBs are cultured on 0.1% gelatin-coated dishes for 14 d using CF culture medium for the outgrowth of cardiac structures. At this stage, iPS cells undergoing EB formation are termed iPS derivates (iPSD)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

213.24

Formula

C₁₂H₁₁N₃O

CAS No.

91396-88-2

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PluriSln 1
Cat. No.:
HY-15700
Quantity: